MedPath

Clotting With Different Dialyzer Membranes

Completed
Conditions
Kidney Failure
Registration Number
NCT02546037
Lead Sponsor
University College, London
Brief Summary

Primary Objective:

The purpose of this study is to measure the amount of convection achieved with two different haemodiafilters designed for haemodiafiltration and clotting during haemodiafiltration treatment.

Detailed Description

This is a prospective observational cohort pilot study of patients under the care of the Royal Free Hospital with chronic kidney disease who have been established on regular thrice weekly haemodiafiltration treatments in a dialysis centre. Information on the study will be disseminated to the Royal Free consultant nephrologists at the dialysis centre with primary responsibility for the individual patient.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria
  • Patients age 18 years and older up to 80 years
  • Under the care of the Royal Free Hospital with chronic kidney disease and established on regular thrice weekly haemodiafiltration.
  • Able to provide written informed consent obtained
Exclusion Criteria
  • Patients scheduled for a kidney transplant
  • Patients taking concomitant systemic anticoagulants
  • Patients with known prothrombotic or bleeding disorders
  • Patients with abnormal platelet counts
  • Patients unable to provide written informed consent
  • Patients not fulfilling inclusion criteria

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
convective volume exchangedday 1

volume of convective exchange achieved during the HDF session

Secondary Outcome Measures
NameTimeMethod
visual coagulationday 1

visual analogue score assessment of clotting in the extracorporeal circuit

platelet and coagulation pathway activationday 1

measurement of coagulation pathway proteins and platelet activation markers

small and middle sized solute clearancesday 1

dialyzer clearance of small and middle sized molecules, including urea and beta 2 microglobulin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.